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A molecular design strategy to construct the near-infrared fluorescent 
probe for selectively sensing human cytochrome P450 2J2 
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ABSTRACT 
Cytochrome P450 2J2 (CYP2J2), a key enzyme responsible for oxidative metabolism of 
various xenobiotics and endogenous compounds, participates in a diverse array of 
physiological and pathological processes in humans. Its biological role in tumorigenesis and 
cancer diagnosis remains poorly understood, owing to the lack of molecular tools suitable for 
real-time monitoring CYP2J2 in complex biological systems. Using molecular design 
principles we were able to modify the distance between the catalytic unit and metabolic 
recognition moiety, allowing us to develop a CYP2J2 selective fluorescent probe using a near-
infrared fluorophore (E)-2-(2-(6-hydroxy-2, 3-dihydro-1H-xanthen-4-yl)vinyl)-3,3- dimethyl-
1-propyl-3H-indol-1-ium iodide (HXPI). To improve the reactivity and isoform specificity, a 
self-immolative linker was introduced to the HXPI derivatives in order to better fit the narrow 
substrate channel of CYP2J2, the modification effectively shortened the spatial distance 
between the metabolic moiety (O-alkyl group) and catalytic center of CYP2J2. After screening 
a panel of O-alkylated HXPI derivatives, BnXPI displayed the best combination of specificity, 
sensitivity and applicability for detecting CYP2J2 in vitro and in vivo. Upon O-demethylation 
by CYP2J2, a self-immolative reaction occurred spontaneously via 1,6-elimination of p-
hydroxybenzyl resulting in the release of HXPI. Allowing BnXPI to be successfully used to 
monitor CYP2J2 activity in real-time for various living systems including cells, tumor tissues, 
and tumor-bearing animals. In summary, our practical strategy could help the development of 
a highly specific and broadly applicable tool for monitoring CYP2J2, which offers great 
promise for exploring the biological functions of CYP2J2 in tumorigenesis.  
Introduction 
Cytochrome P450s (CYPs) is part of a superfamily of multifunctional heme-thiolate proteins 
that play crucial roles in the oxidative metabolism of various xenobiotics and endogenous 
compounds. CYP2J2, as a key member of the CYPs superfamily, can metabolize endogenous 
polyunsaturated fatty acids to form vital signaling molecules, resulting in the formation of 
epoxyeicosatrienoic acids (EETs) and ultimately promotes cell progression.1 It is mainly 
expressed in cardiovascular systems including heart and vascular endothelium2-4 and in a large 
number of cancers.5-8 Recently, the available data suggest that high levels of CYP2J2 
expression is directly associated with tumorigenesis, and overexpression of CYP2J2 in various 
carcinoma cell lines (including Tca-8113, A549, Ncl-H446, and HepG2) would promote 
proliferation and protect the cells against apoptosis. Meanwhile, CYP2J2 was shown to 
produce several pro-angiogenic lipid products and contribute to metastasis of the tumor by 
promoting the angiogenesis in and around primary tumors.6-8 Thus, CYP2J2 could be regarded 
as a vital biomarker for cancer diagnosis and treatment. 
The requirements for the dynamic monitoring of CYP2J2 activity in living systems are 
strong motivators for the development of novel methods for the detection in various biological 
systems. Traditional detection methods used for CYP2J2 activity mainly rely upon mass 
spectrometry or high-performance liquid chromatography,9,10 which are not suitable for live-
specimen evaluation. Fluorescence imaging is an efficient method to simply, safely and 
sensitively monitor enzymatic activity in cells, tissues and animals, offering high 
spatiotemporal resolution, noninvasive capability and can be used in living organisms.11-16 
Various enzyme-activatable fluorescent probes have been developed for real-time monitoring 
enzyme activity and widely utilized in biological research, medical diagnosis and even 
intraoperative visualization of various diseases.17-19 Among the fluorescent probes for sensing 
protein biomarkers, near-infrared (NIR) imaging reporters have enabled minimization of tissue 
background fluorescence and light scattering, as well as improvement of photon penetration 
through deep tissue, thereby providing more accurate imaging or functional evaluation in living 
systems.20-25 Thus, activatable NIR fluorescent probe(s) for real-time sensing CYP2J2 activity 
in living systems are highly desirable, and may facilitate further investigation into the 
enzymatic functions and diagnosis of the diseases associated with CYP2J2.    
However, the development of fluorescent probes for the selective monitoring of target 
enzymes are a significant challenge, due to the size and shape limits of enzymatic cavities and 
the complicated substrate recognition process between enzymatic catalytic sites and small 
molecular fluorophores.11,26-29 Even if potential fluorophores can enter into the active cavity of 
the enzyme like a key inserting into a lock, improper spatial distances between the expected 
metabolic site of the fluorophores and the catalytic center of the target enzyme can seriously 
restrict the activation of the fluorescent probe by the target enzyme, the analogue being that the 
key does not open the lock. Therefore, the rational design of a "best-fit" fluorescence molecule 
to achieve highly effective catalysis towards a target enzyme is essential for success. To solve 
this challenge, a specific fluorescent probe for CYP2J2 was designed and developed based on 
the active cavity structure, catalytic characteristic and substrate preference of CYP2J2. To the 
best of our knowledge, the substrate channel of CYP2J2 is characterized by a cylinder that 
narrows near the heme prosthetic group, therefore limiting substrate access to the active heme 
iron for further oxidation.30,31 Although the active cavity volume for CYP2J2 is similar to that 
of CYP3A4 (a typical CYP with larger active cavity),32 CYP2J2 is restricted to the metabolism 
of substrates with rigid and bulkier structures. 
The great challenge in the design and development of an activatable fluorescent probe for 
CYP2J2 is how to effectively modify the fluorophore to fit the enzymatic active cavity and 
adjust the recognition moiety to improve reactivity. Therefore, adjustment of the fluorophore 
to adapt to the narrow shape of the substrate channel of CYP2J2 is a suitable strategy to 
facilitate the development of CYP2J2 sensors. In the present study, (E)-2-(2-(6-hydroxy-2, 3-
dihydro-1H-xanthen-4-yl)vinyl)-3,3-dimethyl-1-propyl-3H-indol-1-ium iodide (HXPI) was 
selected as the basic fluorophore, as it possesses a long aromatic skeleton and has desirable 
photophysical properties, excellent tissue penetration, and results in minimal biological 
damage.20-25 Meanwhile, we hypothesized that a self-immolative linker (e.g. p-hydroxybenzyl 
group) could be employed as a linker moiety that could adjust the fluorophore to adapt to the 
structure of CYP2J2 and shorten the spatial distance between the metabolic site of the substrate 
and the catalytic center of CYP2J2. The metabolic recognition moiety (O-alkyl group) of the 
fluorescence chemosensor was optimized in order to improve the reactivity and isoform-
selectivity towards CYP2J2. As expected, upon addition of CYP2J2, the p-hydroxybenzyl ether 
derivatives consistently displayed significantly higher fluorescence response than the 
corresponding O-alkylated HXPI derivatives. The self-decomposition of p-hydroxybenzyl is 
triggered by CYP2J2-mediated O-demethylation, spontaneously releasing a NIR fluorescence 
signal. Therefore, by simultaneously optimizing catalytic distance and the metabolic 
recognition moiety, a highly selective NIR florescence probe of CYP2J2 (BnXPI) was 
successfully developed for the real-time monitoring of endogenous CYP2J2 activity in 
complex biological systems (Scheme 1). Furthermore, we demonstrated the feasibility and 
practicability of the CYP2J2-activatable fluorescent probe for real-time imaging and disease 
diagnosis, and characterized the potential role played by CYP2J2 in various tumor-associated 
processes.  
RESULTS AND DISCUSSION 
Design and synthesis 
Currently, the development of an activatable and subtype-selective probe remains a great 
challenge, due to restricted access of fluorogenic substrates to the active cavity of the target 
enzyme, resulting in a mismatch of the ‘lock-and-key’. Therefore, flexible molecules with 
conformational flexibility, are recognized and metabolized by CYP2J2. To confirm this 
assumption, we collected a series of fluorophores possessing either conformational flexibility 
or rigidity, and their corresponding methylated compounds were designed and synthesized 
(Figure S1). The in silico docking analyses and in vitro CYP2J2 incubation assays were 
performed. As shown in Figure S2 and Table S1, our molecular strategy described above was 
rational, and comprehensively considers the reactivity, selectivity and fluorescence properties 
of potential probes for detecting CYP2J2. (E)-2-(2-(6-hydroxy-2, 3-dihydro-1H-xanthen-4-
yl)vinyl)-3,3-dimethyl-1-propyl-3H-indol-1-ium iodide (HXPI), a well-known NIR dye,33 was 
selected as the basic fluorophore with the flexibility suitable for matching CYP2J2. However, 
probe 1 (MXPI, as shown in Scheme 1A), did not fulfill the requirements as a highly-effective 
substrate of CYP2J2 (namely the key could be inserted into the lock, but it does not open the 
lock). Therefore, we should optimize this ‘key’ to obtain the ‘best-fit’ fluorescent probe that 
could achieve effective interaction between the metabolic recognition site and catalytic cavity 
of CYP2J2.   
According to the 3D-structure and metabolic characteristics of CYP2J2, our design strategy 
was to introduce a self-immolative linker into HXPI for improving the catalytic efficiency of 
dealkylation by shortening the spatial distance between the metabolic recognition moiety (O-
alkyl group) and the catalytic center of CYP2J2, which will help HXPI derivatives adapt to the 
cylinder and narrow substrate access channel nearby to the heme prosthetic group of CYP2J2 
(Scheme 1A). Inspired by the structural characteristic of astemizole, a classical substrate of 
CYP2J2, with a benzene ring that could facilitate the interaction between ligand and heme of 
CYP2J2 through π-π stacking (Figure S3), we designed and synthesized a panel of HXPI 
derivatives combining the self-immolative linker (p-hydroxybenzyl) along with various 
alkoxyl groups as the metabolic recognition moieties (Scheme 1B). Our aim was to improve 
the sensitivity and isoform-specificity for CYP2J2 by adjusting the alkyl groups (such as ethyl, 
isopropyl, benzyl, etc) on the self-immolative linker. The HXPI derivatives could be readily 
synthesized and their structures were fully characterized by 1H NMR, 13C NMR and HRMS 
spectra (Scheme S1, Supporting Information). The reactivity and isoform phenotype screening 
revealed that O-alkylated HXPI derivatives with self-immolative linkers (probe 5–8) displayed 
good reactivity towards CYP2J2. In contrast, HXPI derivatives without the linker (probe 1–4) 
could hardly be catalyzed by CYP2J2, and displayed relatively weak fluorescence response 
and low isoform-specificity. Among all the p-hydroxybenzyl ether derivatives, BnXPI (probe 
5) gave the highest fluorescence turn-on response towards CYP2J2. The self-decomposition of 
BnXPI is triggered by a CYP2J2-mediated O-demethylation that produces a labile linker 
HXPI derivative, and spontaneously produces a strong NIR fluorescence signal. The formation 
of HXPI mediated by CYP2J2 in the reaction system was confirmed by a comprehensive 
comparison of LC retention times, UV and MS spectra with standard compounds (Figure S4).  
The in silico docking analyses elucidated the role of the self-immolative linkers on the 
catalytic distance, and further verified our design strategy. As shown in Scheme 1B, the spatial 
distance of the O-methyl group of BnXPI with the catalytic center of HEME inside the CYP2J2 
cavity was calculated as 3.8 Å, which was shorter than that of MXPI (5.75 Å). In other words, 
the catalytic distance of BnXPI was effectively shortened by introducing the p-hydroxybenzyl 
ether moiety, which enhanced the catalytic efficiency of CYP2J2 for O-demethylation of HXPI 
derivatives. Notably, the π-π stacking interaction between the benzene ring of BnXPI and the 
HEME ring of CYP2J2, as well as the H-bonding interaction between the methoxyl group of 
BnXPI and Thr-315 of CYP2J2, may contribute significantly to the molecular interaction of 
BnXPI with the HEME ring of CYP2J2, all of which indicated that BnXPI orients itself 
markedly better than MXPI (probe 1, without self-immolative linker) in the active site of 
CYP2J2 (Figure S5 and S6). These results implied that the linker groups on BnXPI moved the 
substrates closer to the catalytic center of CYP2J2, as expected from our design strategy (a key 
of appropriate length was inserted into the lock, and could turn to open the door). Furthermore, 
the chemscore value of the bioactive pose of MXPI and BnXPI in CYP2J2 is -32.71 and -
49.31, respectively, which is consistent with the demethylation rate of these two compounds 
(Table S2). Generally, our molecular design strategy succeeded in optimizing the HXPI 
derivatives to fit the shape of the substrate channel of CYP2J2 by effectively shortening the 
catalytic distance and adjusting the recognition moieties to achieve an overall ‘best-fit’ probe. 
Therefore, our strategy was able to improve the reactivity and selectivity of the fluorescent 
probe toward CYP2J2.  
 
Scheme 1. (A) Design strategy using a self-immolative linker for improving the catalytic rate 
for CYP2J2. The optimization of the probe was based on adjusting the catalytic distance and 
recognition moiety. (B) The characteristic structures of O-alkoxyl HXPI derivatives without 
(Probe 1-4) or with (Probe 5-8) a p-hydroxybenzyl moiety. The fluorescence response of HXPI 
derivatives at 718 nm (λex = 656 nm) upon the addition of CYP2J2 for 30 min. Docking 
simulation of probe 1 (MXPI) and probe 5 (BnXPI) into CYP2J2, with the catalytic distances 
shown.  
Spectral properties of BnXPI toward CYP2J2 
To test the validity of this probe, the spectral properties of BnXPI were investigated. Upon 
addition of CYP2J2, the fluorescence intensity gradually increased at 718 nm (Figure 1). 
Furthermore, the fluorescence intensity increased linearly when CYP2J2 was progressively 
added from 0 to 0.45 mg/mL (R2 = 0.974). Clearly, the distinct fluorescence response confirmed 
CYP2J2-mediated dealkylation of BnXPI to liberate the oxygen atom as a strong electron 
donor in the D–π–A structure, thereby increasing the intra-molecular charge transfer (ICT). 
Upon treatment with CYP2J2, a remarkable change in UV absorption profile of BnXPI was 
also observed, and a color variation from blue to cyan allowed the direct colorimetric detection 
of CYP2J2 (Figure S7). BnXPI was quite stable over a pH range from 7.0 to 12.0, and the pH 
values did not affect the fluorescence intensity of both BnXPI and HXPI over this pH range 
(Figure S8). Together, these results demonstrate that BnXPI could be used to detect the 
CYP2J2 activity under physiological conditions (pH 7.4). 
 
Figure 1. (A) Proposed mechanism of CYP2J2 triggering the fluorescence response of BnXPI. 
(B) Fluorescence spectra of BnXPI (10 μM) upon the addition of increasing concentrations of 
CYP2J2 and incubated for 30 min. λex = 656 nm. (C) Fluorescence intensity of BnXPI at 718 
nm upon the addition of increasing concentrations of CYP2J2 and incubated for 30 min.  
Selectivity and sensitivity of BnXPI towards CYP2J2  
The selectivity of BnXPI was characterized using a panel of CYP isoforms expressed in 
various human organs and carcinoma.5,34-36 It was found that only CYP2J2 could provoke 
BnXPI to generate a significant fluorescence, over other enzymes evaluated (Figure S9). The 
HXPI formation rates of CYP2J2 are 46-fold higher than that of other CYPs. As shown in 
Figure S10, BnXPI exhibited high selectivity for CYP2J2 over the other potential interfering 
species. Our results indicate that BnXPI O-demethylation was selectively catalyzed by 
CYP2J2 even in complex biological matrixes. 
The detection limit of BnXPI for sensing CYP2J2 was measured as 0.024 mg/mL, indicating 
the ultra-sensitivity of BnXPI to detect CYP2J2 bioactivity (Figure S11). The apparent 
substrate affinity constant (Km) value of CYP2J2 for BnXPI O-demethylation was determined 
as 4.2 μM (Figure S12). The excellent selectivity and sensitivity of the fluorescence-based 
assay implied that BnXPI enables the rapid and precise detection of CYP2J2 in complex 
biological samples. Subsequently, a selection of investigations were performed to evaluate the 
quantitative detection and selective imaging capability of CYP2J2 in biological samples 
including cancer cells, human tissues and the living model of tumor migration and angiogenesis. 
Quantification of CYP2J2 in human tissue microsomes. 
The catalytic activities of CYP2J2 in a panel of 13 liver microsomes (HLM) from individual 
humans are determined (Figure 2A) using BnXPI. There was more than 3-fold variation in 
catalytic activity, which was according to the variation of CYP2J2 protein content in HLM.37 
To verify the ability of BnXPI to interact selectively with CYP2J2, the correlation analysis was 
carried out between the reaction rate of BnXPI-O-demethylation and the corresponding 
catalytic activities of CYP2J2, which was determined by a traditional non-florescence based 
probe (astemizole, AST). As shown in Figure 2B, the O-demethylation rates of BnXPI were 
highly correlated with the metabolic rates of astemizole in these individual HLM.   
 
Figure 2. (A) The catalytic activity of CYP2J2 in 13 individual HLM using BnXPI as probe 
substrate. (B) Correlation analysis of metabolic rates of BnXPI (10 μM) and AST (10 μM) 
mediated by CYP2J2. Dose-inhibition curves of danazol (C) and ketoconazole (D) on O-
demethylation of BnXPI and AST.   
Recent research has demonstrated the key role of CYP2J2 in the pathogenesis of a variety 
of human cancers,5,38 indicating the selective inhibition of CYP2J2 may be a promising 
therapeutic strategy against cancer.38,39 In our present work, two known inhibitors of CYP2J2 
such as danazol (DNZ) and ketoconazole (TKZ) were used. Their inhibitory effects are similar 
when using BnXPI and the non-florescence based probe astemizole. Indicating that the 
BnXPI-based fluorescence detection method for CYP2J2 activity could be used for the rapid 
and quantitative measurement of CYP2J2 activities, instead of traditional detection methods 
(Figure 2C and 2D). These findings suggested that BnXPI could serve as a highly selective 
fluorescent probe for high-throughput screening and accurate characterization of CYP2J2 
inhibitors.   
Bioimaging in Living Cells.  
To demonstrate the potential of BnXPI for quantitatively detecting endogenous CYP2J2 
activity in intact cells, a variety of human cancer cells from different sources were used as 
model cells. Prior to biological imaging in living cells, the cell viability of A549 and HepG2 in 
the presence of BnXPI and HXPI were evaluated using a standard CCK-8 assay. As shown in 
Figure S13 and S14, both BnXPI and HXPI exhibited relatively low toxicity toward the cells 
examined. BnXPI (2.5 µM) was then used for imaging endogenous CYP2J2 in living cells. 
U251, HepG2, A549 and K562 cells were incubated with BnXPI at 37 °C for 1 h and 
subsequently washed to remove the residual probe. There was a strong fluorescence 
enhancement for the cells evaluated (Figure 3A). To clarify whether the fluorescence turn-on 
was triggered by the cellular CYP2J2, chemical inhibition experiments were performed, where 
cells were treated with DNZ (10 µM) or TKZ (50 µM). As shown in Figure S15, pretreatment 
with DNZ or TKZ resulted in suppressed fluorescence. The origins of the fluorescence were 
further confirmed by immunoblot analysis of CYP2J2 protein in cell lysates (Figure 3B and 
3C). All the above results proved that the intracellular fluorescence signal could be ascribed to 
the CYP2J2 mediated activation of BnXPI. Collectively, these results confirmed that BnXPI 
can be used to measure endogenous CYP2J2 levels in a variety of cellular contexts.  
 Figure 3. Bioimaging (A) and graphical quantification of average fluorescence intensity (B) 
of CYP2J2 activities by BnXPI in living human cancer cells. The scale bar is 25 μm. BnXPI: 
excitation, 633 nm; semiconductor laser emission, 690−750 nm. (C) The protein level of 
CYP2J2 in tumor cells was analyzed by western blot using glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) as an internal reference.  
Given migration is regarded as the core hallmark of cancer manifesting with malignant 
transformation ability, the potential role of CYP2J2 on migration was investigated. We detected 
the consequences of silencing CYP2J2 on A549 cell motility as well as BnXPI imaging 
performance during this biological process. After pretreating with siRNA, A549 cells exhibited 
a suppressed fluorescence signal, which was in agreement with the markedly reduced protein 
level of CYP2J2 (Figure S16). As shown in Figure S17, the migration ability of CYP2J2 
silenced cells was impaired so that the scraped space was not occupied by cells. These results 
demonstrate the application of BnXPI for tumor cell analysis, such as migration assay. 
Furthermore, these results imply that CYP2J2 plays an important role in the acceleration of 
cancer migration, while its inhibition may be a promising anti-cancer therapeutic approach. 
Bioimaging of angiogenesis by BnXPI in vitro and ex vivo 
Angiogenesis plays a vital role in the growth and spread of cancer, given that an adequate blood 
supply is necessary for tumor growth and invasion into normal tissue.40,41 CYP2J2 is a key 
enzyme responsible for the conversion of arachidonic acid to pro-angiogenic epoxy metabolite 
EETs. Therefore, the biological function of CYP2J2 in carcinogenesis has attracted significant 
attention.42-45 Inspired by the high expression of CYP2J2 in vascular endothelial cells,2-4 we 
examined the capability of BnXPI for the visualization of human umbilical vein endothelial 
cells (HUVEC) and monitoring the neovessel formation in the constructed angiogenesis 
models. As expected, a strong fluorescence enhancement was observed in HUVEC after 
incubation with BnXPI. Furthermore, HUVEC pretreated with CYP2J2 selective inhibitors 
(danazol or ketoconazole) or CYP2J2 siRNA, exhibited a significantly suppressed fluorescence 
signal (Figure S18 and S19). We then evaluated an in vitro tube formation angiogenesis model. 
BnXPI can clearly indicate tubular morphogenesis of HUVEC (Figure 4A-i), and the migration 
and tube-forming ability of cells that were pretreated with CYP2J2 siRNA or inhibitors was 
significantly impaired (Figure 4A-iii, v, vii, ix). It should be noted that the correlation between 
CYP2J2 activity and HUVEC migration was visualized using CYP2J2 activatable sensor 
(BnXPI). Subsequently, the capacity of BnXPI for monitoring the neovessel formation was 
verified by a 3D spheroid sprouting and an ex vivo neonatal ventricle culture assay.46 We found 
that BnXPI could precisely elucidate neovessels sprouted from 3D spheroid sprouting (Figure 
4B) and the heart tissues (Figure 4C). These results indicate that BnXPI can provide a NIR 
readout for the in situ quantitative tracking of endogenous CYP2J2 activity and visualization 
of neovessels in an angiogenesis model. Notably, the down regulation of CYP2J2 by siRNA as 
well as inhibition of CYP2J2 activity by chemical inhibitors could effectively inhibit the tube-
formation of endothelial cells. We believe that the 3D visible method of angiogenesis using 
BnXPI could lead to an explosion of research to discover novel CYP2J2 mediators-induced 
anti-angiogenesis therapeutics.  
 
Figure 4. Bioimaging of angiogenesis using BnXPI in vivo and ex vivo. (A) Confocal 
fluorescence imaging of tube formation in matrigel angiogenesis assay. Images of endothelial 
cell tube (i-ii), CYP2J2 knockdown cell tube (iii-iv), TKZ (v-vi) or DNZ (vii-viii) pretreated 
cell tube. (B) Imaging of endothelial cell spheroids. Cell spheroids were pretreated with siRNA 
(iv-vi), TKZ (vii-ix) or DNZ (x-xii). (C) Imaging of endothelial cell sprouting from three-
dimensional heart angiogenesis assay. BnXPI (red), immunofluorescence for CYP2J2 (pink), 
FITC-Lectin (green). Scale bar is 250 μm.  
Bioimaging by BnXPI in bio-specimens of clinical patients with haematological 
malignancies 
We then examined whether CYP2J2 activity in peripheral blood white cells can be detected 
using BnXPI, aiming to develop a diagnostic tool for human haematologic malignancies.47-50 
For this purpose, we set out to examine whether BnXPI could detect CYP2J2 activities in six 
samples of peripheral blood collected from different patients with leukemia and lymphoma. 
The detailed clinical data and CYP2J2 expression of patients is given in Figure S20 and Table 
S3. We succeeded in detecting CYP2J2 activity in peripheral blood white cells from patients 
(Figure 5A). Furthermore, the fluorescence signal verified by flow cytometry, was directly 
proportional to the CYP2J2 expression measured by western blot (Figure 5B and 5C). The very 
weak fluorescence emission of HXPI in samples of healthy volunteers are attributed to the low 
protein levels of CYP2J2 in normal peripheral blood, which agrees with previous research.48 
Subsequently, BnXPI was tentatively used as a prognostic indicator for acute myeloid 
leukeamia. The dramatic rise of immature stem cells and myeloblasts in the plasma of patients 
with acute myeloid leukeamia was effectively elucidated by BnXPI-based imaging assisted by 
CD34 and CD117 analysis (Figure S21). Thus, we performed the real-time imaging of the 
abnormal surplus of white cells in peripheral blood using BnXPI, which provided some 
important information for the diagnosis, classification and monitoring of hematological 
malignancies. 
  
Figure 5. Confocal fluorescence imaging (A) and flow cytometric analyses (B) of CYP2J2 
activities in peripheral white blood cells from healthy volunteers (N1-N6) and patients with 
leukemia or lymphoma (P1-P6). Scale bar is 50 μm. (C) Protein level of CYP2J2 in peripheral 
white blood cells analyzed by western blot using GAPDH as an internal reference. 
Real-time In Vivo Imaging of CYP2J2 Activity in Tumors 
Inspired by the distinct ‘light-up’ NIR emission, we examined the capability of BnXPI for real-
time in vivo visualization of CYP2J2 activity of tumors. Owing to amplified fluorescence by 
enzymatic turnover and particularly low background interference in the NIR region, a NIR 
fluorescent signal was observed rapidly in the tumor region after injection of BnXPI into the 
tumor (Figure 6A). It should be noted that, just after 10 min post injection, the NIR fluorescence 
signal was observed and had spread to the whole tumor region, indicative of the rapid activation 
and high sensitivity of BnXPI for CYP2J2. The fluorescence intensity gradually increased, 
reaching a maximum level after 1 h post injection, and then slowly decayed over time. We 
further recorded the ex vivo fluorescence images of tumor and adjacent normal tissue collected 
immediately after sacrificing the mice, and the adjacent tissues of cancer displayed no 
fluorescence signal (Figure 6B). The imaging of CYP2J2 in tumor tissue sections after staining 
with BnXPI was preformed upon excitation at 633 nm, and the remarkable fluorescence image 
induced by CYP2J2 is in good accordance with the immunohistochemical staining with 
CYP2J2 antibodies. Additionally, excellent results were also observed for the imaging of 
human tumor sections (Figure S22). Taken together, these findings indicate that BnXPI is a 
useful molecular tool for imaging CYP2J2 in tumors and tissue sections, which could be used 
for surgical diagnosis and therapy of cancers in clinics.  
 
Figure 6. (A) In vivo NIR fluorescence imaging of CYP2J2 in tumor-bearing nude mice after 
tumor injection. The grown tumor tissue was taken from the mouse. (B) Fluorescence (left) and 
immunofluorescence (right) images of the CYP2J2 in tumor tissue slice. Scale bar is 50 μm. 
BnXPI (red): excitation, 633 nm; semiconductor laser emission collected, 690−750 nm. 
Immunofluorescence for CYP2J2 (green): excitation, 543 nm; emission collected, 590−650 nm. 
CONCLUSION  
Using a structure-based molecular design strategy, we have successfully developed the first 
near-infrared (NIR) activatable fluorescent probe for the selective and real-time detection of 
CYP2J2. According to the structural features and substrate preference of CYP2J2, a 
dealkylation-based trigger utilizing a self-immolative linker attached to HXPI, was critical in 
facilitating the excellent “Lock and Key” fit, in order to facilitate the O-dealkylation of HXPI 
derivatives. After screening and optimization, BnXPI displayed the ideal combination of 
selectivity, sensitivity and NIR fluorescence response following CYP2J2-mediated O-
demethylation. BnXPI could be specifically activated in various cancer cells and the 
neovessels of endothelial cells, thereby providing a light-up readout for the quantitative 
tracking of endogenous CYP2J2 activity and visualization of the angiogenesis process. 
Furthermore, BnXPI has been successfully applied for the real-time imaging of CYP2J2 in 
tumor-bearing mice. In summary, a new NIR fluorescence based probe BnXPI has been 
developed and fully characterized for sensitive detection of CYP2J2, which holds great promise 
for CYP2J2-associated carcinoma diagnosis and treatment, and for further investigations into 
the potential biological functions of CYP2J2. Furthermore, our practical strategy facilitates a 
new route for developing enzyme-activatable and isoform-specific fluorescent probes for target 
enzymes. 
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